ReviewLeukemia2005
New insight into the molecular mechanisms of MLL-associated leukemia.
Review in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 54 citations in OpenAlex.
- HOXB5 in precision oncology: regulatory networks, functional duality, and clinical prospects.Journal of translational medicine · 2026Review
- MAT2A as Key Regulator and Therapeutic Target inCancers · 2020Article
- Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- 11q23 abnormalities in adult Chinese patients with hematological malignancies.Medical oncology (Northwood, London, England) · 2014Article
- Novel domain combinations in proteins encoded by chimeric transcripts.Bioinformatics (Oxford, England) · 2012Article
- Therapy-related acute lymphoblastic leukemia with t(4;11)(q21;q23) masqueraded as marrow lymphocytosis in a patient with breast cancer.The Kaohsiung journal of medical sciences · 2012Article
- Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.European journal of pediatrics · 2011Review
- Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.Blood · 2010Article
- MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures.BMC medical genomics · 2009Article
- C/EBPalpha and C/EBPvarepsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene.Oncogene · 2008Article
- Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.Clinical pharmacology and therapeutics · 2008Review
- Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence.BMC developmental biology · 2008Article
- DNA topoisomerase II, genotoxicity, and cancer.Mutation research · 2007Review
- Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.Journal of clinical pathology · 2007Article
- SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23).Oncogene · 2006Article
- ArgBP2, encoding a negative regulator of ABL, is fused to MLL in a case of infant M5 acute myeloid leukemia involving 4q35 and 11q23.Leukemia · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rearrangements of the MLL gene (ALL1, HRX, and Hrtx) located at chromosome band 11q23 are commonly involved in adult and pediatric cases of primary acute leukemias and also found in cases of therapy-related secondary leukemias. Studies on mouse models of MLL translocation and cell lines containing MLL rearrangements showed that the MLL gene linked chromosomal rearrangements to cellular differentiation and tumor tropism. Moreover, recent structural/functional studies on MLL and aberrant MLL proteins provided new clues and suggested that different mechanisms might be included in leukemogenesis by MLL rearrangements. The connection between these different mechanisms will help us understand globally how aberrant MLL oncogenes affect the normal cellular processes at molecular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.